C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system

Jacob C. A. Edvinsson1,2, Karin Warfvinge3,1, Diana N. Krause3,4, Frank W. Blixt5, Majid Sheykhzade2, Lars Edvinsson1,3, Kristian A. Haanes1
1Department of Clinical Experimental Research, Copenhagen University Hospital, Rigshospitalet-Glostrup, Copenhagen, Denmark
2Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
3Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, Lund, Sweden
4Department of Pharmacology, School of Medicine, University of California at Irvine, Irvine, USA
5Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, USA

Tóm tắt

Monoclonal antibodies (mAbs) towards CGRP or the CGRP receptor show good prophylactic antimigraine efficacy. However, their site of action is still elusive. Due to lack of passage of mAbs across the blood-brain barrier the trigeminal system has been suggested a possible site of action because it lacks blood-brain barrier and hence is available to circulating molecules. The trigeminal ganglion (TG) harbors two types of neurons; half of which store CGRP and the rest that express CGRP receptor elements (CLR/RAMP1). With specific immunohistochemistry methods, we demonstrated the localization of CGRP, CLR, RAMP1, and their locations related to expression of the paranodal marker contactin-associated protein 1 (CASPR). Furthermore, we studied functional CGRP release separately from the neuron soma and the part with only nerve fibers of the trigeminal ganglion, using an enzyme-linked immunosorbent assay. Antibodies towards CGRP and CLR/RAMP1 bind to two different populations of neurons in the TG and are found in the C- and the myelinated Aδ-fibers, respectively, within the dura mater and in trigeminal ganglion (TG). CASPR staining revealed paranodal areas of the different myelinated fibers inhabiting the TG and dura mater. Double immunostaining with CASPR and RAMP1 or the functional CGRP receptor antibody (AA58) revealed co-localization of the two peptides in the paranodal region which suggests the presence of the CGRP-receptor. Double immunostaining with CGRP and CASPR revealed that thin C-fibers have CGRP-positive boutons which often localize in close proximity to the nodal areas of the CGRP-receptor positive Aδ-fibers. These boutons are pearl-like synaptic structures, and we show CGRP release from fibers dissociated from their neuronal bodies. In addition, we found that adjacent to the CGRP receptor localization in the node of Ranvier there was PKA immunoreactivity (kinase stimulated by cAMP), providing structural possibility to modify conduction activity within the Aδ-fibers. We observed a close relationship between the CGRP containing C-fibers and the Aδ-fibers containing the CGRP-receptor elements, suggesting a point of axon-axon interaction for the released CGRP and a site of action for gepants and the novel mAbs to alleviate migraine.

Từ khóa


Tài liệu tham khảo

Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14(6):338–350 Edvinsson L (2017) The Trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 57(Suppl 2):47–55 Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U et al (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350(11):1104–1110 Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M et al (2019) Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs. 79(4):417–431 Boado RJ, Zhou QH, Lu JZ, Hui EK, Pardridge WM (2010) Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol Pharm 7(1):237–244 Edvinsson L, Tfelt-Hansen P (2008) The blood-brain barrier in migraine treatment. Cephalalgia. 28(12):1245–1258 Hougaard A, Amin FM, Christensen CE, Younis S, Wolfram F, Cramer SP et al (2017) Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain. 140(6):1633–1642 Amin FM, Hougaard A, Cramer SP, Christensen CE, Wolfram F, Larsson HBW et al (2017) Intact blood-brain barrier during spontaneous attacks of migraine without aura: a 3T DCE-MRI study. Eur J Neurol 24(9):1116–1124 Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L (2013) Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain 14(11):1289–1303 Schain AJ, Melo-Carrillo A, Stratton J, Strassman AM, Burstein R (2019) CSD-induced arterial dilatation and plasma protein extravasation are unaffected by Fremanezumab: implications for CGRP's role in migraine with Aura. J Neurosci 39(30):6001–6011 Melo-Carrillo A, Strassman AM, Nir RR, Schain AJ, Noseda R, Stratton J et al (2017) Fremanezumab-a humanized monoclonal anti-CGRP antibody-inhibits thinly Myelinated (Adelta) but not unmyelinated (C) meningeal Nociceptors. J Neurosci 37(44):10587–10596 Haanes KA, Edvinsson L (2019) Pathophysiological mechanisms in migraine and the identification of new therapeutic targets. CNS Drugs 33(3):525–537 Zhang L, Kunkler PE, Knopp KL, Oxford GS, Hurley JH (2019) Role of intraganglionic transmission in the trigeminovascular pathway. Mol Pain 15:1744806919836570 Walker CS, Raddant AC, Woolley MJ, Russo AF, Hay DL (2018) CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured. Cephalalgia. 38(3):437–451 Salzer JL (1997) Clustering sodium channels at the node of Ranvier: close encounters of the axon-glia kind. Neuron. 18(6):843–846 Arancibia-Carcamo IL, Attwell D (2014) The node of Ranvier in CNS pathology. Acta Neuropathol 128(2):161–175 Arroyo EJ, Scherer SS (2000) On the molecular architecture of myelinated fibers. Histochem Cell Biol 113(1):1–18 Rios JC, Melendez-Vasquez CV, Einheber S, Lustig M, Grumet M, Hemperly J et al (2000) Contactin-associated protein (Caspr) and contactin form a complex that is targeted to the paranodal junctions during myelination. J Neurosci 20(22):8354–8364 Einheber S, Zanazzi G, Ching W, Scherer S, Milner TA, Peles E et al (1997) The axonal membrane protein Caspr, a homologue of neurexin IV, is a component of the septate-like paranodal junctions that assemble during myelination. J Cell Biol 139(6):1495–1506 Dreisig K, Blixt FW, Warfvinge K (2018) Retinal Cryo-sections, whole-mounts, and hypotonic isolated vasculature preparations for Immunohistochemical visualization of microvascular Pericytes. JoVE (140):e57733 Bhatt DK, Gupta S, Jansen-Olesen I, Andrews JS, Olesen J (2013) NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models. Cephalalgia. 33(2):87–100 Haanes KA, Labastida-Ramírez A, Blixt FW, Rubio-Beltrán E, Dirven CM, Danser AHJ, Edvinsson L, MaassenVanDenBrink A (2019) Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models. Cephalalgia 39(11):1421–1434 Eftekhari S, Edvinsson L (2011) Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. BMC Neurosci 12:112 Miller S, Liu H, Warfvinge K, Shi L, Dovlatyan M, Xu C et al (2016) Immunohistochemical localization of the calcitonin gene-related peptide binding site in the primate trigeminovascular system using functional antagonist antibodies. Neuroscience. 328:165–183 Cottrell GS (2018) CGRP receptor Signalling pathways. Handb Exp Pharmacol Jarnaess E, Tasken K (2007) Spatiotemporal control of cAMP signalling processes by anchored signalling complexes. Biochem Soc Trans 35(Pt 5):931–937 Ghosh A, Sherman DL, Brophy PJ (2018) The axonal cytoskeleton and the assembly of nodes of Ranvier. Neuroscientist. 24(2):104–110 Ebersberger A, Averbeck B, Messlinger K, Reeh PW (1999) Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience. 89(3):901–907 Durham PL, Russo AF (1999) Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci 19(9):3423–3429 Amrutkar DV, Ploug KB, Hay-Schmidt A, Porreca F, Olesen J, Jansen-Olesen I (2012) mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain. 153(4):830–838 Smolen AJ (1988) Morphology of synapses in the autonomic nervous system. J Electron Microsc Tech 10(2):187–204 Egea SC, Dickerson IM (2012) Direct interactions between calcitonin-like receptor (CLR) and CGRP-receptor component protein (RCP) regulate CGRP receptor signaling. Endocrinology. 153(4):1850–1860 Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94(4):1099–1142 Sassone-Corsi P (2012) The cyclic AMP pathway. Cold Spring Harb Perspect Biol 4(12) Scheuer T (2011) Regulation of sodium channel activity by phosphorylation. Semin Cell Dev Biol 22(2):160–165 Liu S, Zheng P (2013) Altered PKA modulation in the Nav1.1 epilepsy variant I1656M. J Neurophysiol 110(9):2090–2098 Arancibia-Carcamo IL, Ford MC, Cossell L, Ishida K, Tohyama K, Attwell D (2017) Node of Ranvier length as a potential regulator of myelinated axon conduction speed. Elife. 6 Shrager P (1989) Sodium channels in single demyelinated mammalian axons. Brain Res 483(1):149–154 Wang H, Kunkel DD, Martin TM, Schwartzkroin PA, Tempel BL (1993) Heteromultimeric K+ channels in terminal and juxtaparanodal regions of neurons. Nature. 365(6441):75–79 Mi H, Deerinck TJ, Ellisman MH, Schwarz TL (1995) Differential distribution of closely related potassium channels in rat Schwann cells. J Neurosci 15(5):3761–3774 Lee JH, Park CK, Chen G, Han Q, Xie RG, Liu T et al (2014) A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief. Cell. 157(6):1393–1404 Yang S, Xiao Y, Kang D, Liu J, Li Y, Undheim EA et al (2013) Discovery of a selective NaV1.7 inhibitor from centipede venom with analgesic efficacy exceeding morphine in rodent pain models. Proc Natl Acad Sci U S A 110(43):17534–17539 Black JA, Frézel N, Dib-Hajj SD, Waxman SG (2012) Expression of Nav1.7 in DRG neurons extends from peripheral terminals in the skin to central preterminal branches and terminals in the dorsal horn. Mol Pain 8:82 Chatelier A, Dahllund L, Eriksson A, Krupp J, Chahine M (2008) Biophysical properties of human Na v1.7 splice variants and their regulation by protein kinase a. J Neurophysiol 99(5):2241–2250 Humphrey PP (2007) The discovery of a new drug class for the acute treatment of migraine. Headache. 47(Suppl 1):S10–S19 Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, Bogaerdt A, Bogers AJJC, Zanelli E, Meeus L, Danser AHJ, Gralinski MR, Senese PB, Johnson KW, Kovalchin J, Villalón CM, MaassenVanDenBrink A (2019) Characterization of binding, functional activity and contractile responses of the selective 5-HT receptor agonist lasmiditan. British Journal of Pharmacology Pascual J, Munoz P (2005) Correlation between lipophilicity and triptan outcomes. Headache. 45(1):3–6 Lundblad C, Haanes KA, Grande G, Edvinsson L. (2015) Experimental inflammation following dural application of complete Freund's adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage. The journal of headache and pain. 16:91 Eftekhari S, Gaspar RC, Roberts R, Chen TB, Zeng Z, Villarreal S et al (2016) Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: a detailed study using in situ hybridization, immunofluorescence, and autoradiography. J Comp Neurol 524(1):90–118 Mierzwa A, Shroff S, Rosenbluth J (2010) Permeability of the paranodal junction of myelinated nerve fibers. J Neurosci 30(47):15962–15968